Mainz Biomed Bv Stock Today

MYNZ Stock  USD 5.34  0.29  5.74%   

Performance

10 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Over 69

 
High
 
Low
Quite High
Mainz Biomed is trading at 5.34 as of the 31st of January 2025; that is 5.74 percent up since the beginning of the trading day. The stock's open price was 5.05. Mainz Biomed has more than 69 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
5th of November 2021
Category
Healthcare
Classification
Health Care
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States.. The company has 2.22 M outstanding shares of which 41.31 K shares are now shorted by private and institutional investors with about 0.3 trading days to cover. More on Mainz Biomed BV

Moving against Mainz Stock

  0.72JNJ Johnson JohnsonPairCorr
  0.7PDSB PDS Biotechnology CorpPairCorr
  0.64NKTX Nkarta IncPairCorr
  0.61INZY Inozyme PharmaPairCorr
  0.54MREO Mereo BioPharma GroupPairCorr
  0.53KRYS Krystal BiotechPairCorr

Mainz Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.06350.0668
Notably Down
Slightly volatile
Total Current Liabilities11.2 M10.6 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total2.7 M3.4 M
Significantly Down
Slightly volatile
Total Assets10.4 M17.7 M
Way Down
Slightly volatile
Total Current Assets8.2 M10.3 M
Significantly Down
Slightly volatile
Debt Levels
Mainz Biomed can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mainz Biomed's financial leverage. It provides some insight into what part of Mainz Biomed's total assets is financed by creditors.
Liquidity
Mainz Biomed BV currently holds 7.42 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Mainz Biomed BV has a current ratio of 10.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Mainz Biomed's use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

2.29 Million
Mainz Biomed BV (MYNZ) is traded on NASDAQ Exchange in USA. It is located in Robert Koch Strasse 50, Mainz, Germany, 55129 and employs 65 people. Mainz Biomed is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.86 M. Mainz Biomed BV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.22 M outstanding shares of which 41.31 K shares are now shorted by private and institutional investors with about 0.3 trading days to cover. Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8.
Check Mainz Biomed Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Mainz Biomed BV is $11.86 Million. Mainz Biomed BV secures 4.98 % of its outstanding shares held by insiders and 0.24 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Mainz Ownership Details

Mainz Biomed Historical Income Statement

At this time, Mainz Biomed's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 977.6 K in 2025, despite the fact that Net Interest Income is likely to grow to (692.2 K). View More Fundamentals

Mainz Stock Against Markets

Mainz Biomed Corporate Management

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.